Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Great. Thanks. So my name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be sitting here with Wade Walke, who's the Vice President of Investor Relations at Ionis. I think we're just going to have Wade kick it off with a 3-minute intro on the company and maybe review recent pipeline and commercial updates on the quarter, and then we can get into Q&A. So Wade, please take it away.
Thanks, Paul. Thanks for inviting me to the conference. Happy to be here. I'm sure a lot of you know about Ionis Pharmaceuticals. We're the leader in RNA-targeted antisense therapy. We have a large pipeline of more than 40 drugs in development. A lot of those in mid- to late-stage development. This year, we'll have 4 programs in Phase III and I think we have over 10-or-so in Phase II development. So a pretty large pipeline of mid- to late-stage assets.
We've developed
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |